アルツハイマー病への経路と,アルツハイマー病からの経路
1Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, 5600 Nathan Shock Drive, Baltimore, Maryland 21224, USA. mattsonm@grc.nia.nih.gov
Nature
|August 6, 2004
まとめ
アルツハイマー病 (AD) は,神経細胞に損傷を与えることで,記憶喪失と認知機能の低下を引き起こす. アルツハイマー病における分子変化を理解することで,神経変性停止または逆転のための新しい治療法が開発される可能性があります.
科学分野:
- 神経科学は神経科学である.
- 病理学 パトロジー
- 薬理学 薬理学とは
背景:
- アルツハイマー病 (AD) は進行性神経変性疾患で,記憶喪失と認知機能低下が特徴です.
- この病気は,情報処理に不可欠なニューロンの機能障害と死によって生じる.
- 現在の治療法は,一時的な症状緩和のみを提供し,病気の進行を止めたり逆転させたりする能力がありません.
研究 の 目的:
- アルツハイマー病の病原性に関する現在の理解を要約します.
- 根底にある神経変性過程を標的とした新しい治療戦略の必要性を強調する.
- 細胞・分子研究における最近の進歩が,効果的な介入策の開発に与える可能性を強調する.
主な方法:
- アルツハイマー病に関する既存の文献のレビュー.
- ADにおける神経変性の原因となる細胞および分子機構の分析.
- AD治療における現在の研究動向の統合.
主要な成果:
- アルツハイマー病は,進行性神経機能障害と死亡を伴うもので,重度の認知および人格の変化につながります.
- 既存の医薬品による介入は,一時的な記憶の改善のみを提供します.
- ADにおけるニューロンの死亡の分子基礎を理解する上で,重要な進展が起こっています.
結論:
- アルツハイマー病に対する効果的な予防と治療戦略が緊急に必要である.
- アルツハイマー病における細胞および分子変化に関する継続的な研究は極めて重要です.
- 疾患メカニズムの理解における進歩は,神経変性障害を止めたり逆転させたりできる将来の治療法への希望を提供します.
関連する概念動画
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
01:23Alzheimer Disease ll: Pathophysiology
42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42
01:24Parkinson Disease ll: Pathophysiology
34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35